References
- Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).
- Miller G. Is pharma running out of brainy ideas? Science 329(5991), 502–504 (2010).
- Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10(6), 428–438 (2011).
- Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11(3), 191–200 (2012).
- Morgan P, Van Der Graaf PH, Arrowsmith J et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17(9–10), 419–424 (2012).
- Arrowsmith J. Trial watch: Phase II failures: 2008–2010. Nat. Rev. Drug Discov. 10, 328–329 (2011).
- Arrowsmith J. Trial watch: Phase III and submission failures: 2007–2010. Nat. Rev. Drug Discov. 10, 87 (2011).
- Millan MJ, Agid Y, Brüne M et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 11(2), 141–168 (2012).
- Green MF, Nuechterlein KH, Gold JM et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56(5), 301–307 (2004).
- Carter CS, Barch DM, Buchanan RW et al. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol. Psychiatry 64(1), 4–10 (2008).
- Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD. Assessing cognitive function in clinical trials of schizophrenia. Neurosci. Biobehav. Rev. 34(8), 1161–1177 (2010).
- Insel T, Cuthbert B, Garvey M et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167(7), 748–751 (2010).
- Bolger FB, McHugh SB, Bennett R et al. Characterisation of carbon paste electrodes for real-time amperometric monitoring of brain tissue oxygen. J. Neurosci. Methods 195(2), 135–142 (2011).
- Francois J, Conway MW, Lowry JP, Tricklebank MD, Gilmour G. Changes in reward-related signals in the rat nucleus accumbens measured by in vivo oxygen amperometry are consistent with fMRI BOLD responses in man. Neuroimage 60(4), 2169–2181 (2012).
- Goldman M. The innovative medicines initiative: a European response to the innovation challenge. Clin. Pharmacol. Ther. 91(3), 418–425 (2012).
Website
- NEWMEDS. www.newmeds-europe.com